Cote d'Ivoire Health

Cipharm is a Côte d’Ivoire-based pharmaceutical company operating since 1988 specialising in the production and marketing of a wide range of generic drugs sold under its own brand and licensed names. The company’s products are sold in French-speaking Sub-Saharan Africa.

We are invested in Cipharm through Cauris Croissance II, which is managed by Cauris Capital Partners II. For further information on the fund, the fund manager, and the expected impact of the fund’s investment, click here.

Key facts


Since 2012, we’ve only invested in Africa and South Asia. Investments outside these regions are from our pre-2012 portfolio.

Africa, West Africa
Cote d'Ivoire

We have seven priority sectors. However, we continue to invest outside these sectors, largely in the most challenging regions, as new investment supporting any sector helps to underpin the private sector, and create jobs and livelihoods for people.

Investment type

We provide capital in three broad ways: direct equity, debt, and intermediated equity (principally through investment funds).

Intermediated investment
Cauris Croissance II
Fund Manager:
Cauris Capital Partners II
Start date

For direct investments, this is the date CDC committed capital to the business or project.

For funds, this is the date that CDC committed capital to the fund.

For underlying fund investments, this is the date that the fund invested capital into the business.e

April 2014